奥沙利铂联合替吉奥胶囊治疗晚期胃癌临床疗效及安全性分析

Effect and safety of oxaliplatin combined with S-1 capsule in the treatment of advanced gastric cancer

目的评价奥沙利铂联合替吉奥胶囊治疗晚期胃癌的临床疗效及安全性。方法选取2011年5月至2016年4月我院收治的80例晚期胃癌患者,随机分为试验组(40例)和对照组(40例)。给予试验组患者奥沙利铂联合替吉奥胶囊治疗,给予对照组患者奥沙利铂联合5-氟尿嘧啶治疗。比较两组患者的治疗总有效率(OR)、疾病控制率(DCR)、总生存期(OS)、无进展生存期(PFS)和不良反应发生情况。结果治疗后,试验组患者的OR为42.5%,DCR为67.5%,OS为9.3个月,PFS为7.7个月,显著高于对照组的20.0%、42.5%、7.4个月、6.1个月(P<0.05)。试验组患者的白细胞减少和恶心呕吐发生率分别为37.5%和45.0%,显著低于对照组的62.5%和67.5%(P<0.05)。结论奥沙利铂联合替吉奥胶囊治疗晚期胃癌的疗效和安全性优于奥沙利铂联合5-氟尿嘧啶。

Objective To evaluate the effect and safety of oxa liplatin combined with S -1 （OXS） in the treatment of advanced gastric cancer （AGC）. Methods Eighty cases of patients with advanced gastric cancer from May 2011 to April 2016 in our hospital were randomly divided into experimental group and control group, with 40 cases in each group. Patients in the experimental group received OXS, while patients in the control group were given oxaliplatin combined 5-fluorouracil （OXF）. The outcomes induding OR, DCR, OS, PFS and adverse events were compared between the two groups. Results The OR, DCR, OS, PFS were 42.5%, 67.5%, 9.3 months, 7.7 months in the experimental group, which were better than 22.0%, 42.5%, 7.4 months and 6.1 months in the control group （P〈0.05）. The rates of leucopenia, nausea and vomiting were 37.5% and 45.0% in the experimental group, which were lower than 62.5% and 67.5% in the control group （P〈0.05）. Conclusion The effect and safety of OXS are superior to the OXF for treating AGC patients.